Castle Biosciences, Inc. Stock News

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced new data showing that DecisionDx-SCC test results positively impacted patient management in over 80% of a Medicare-eligible cohort

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present data highlighting its portfolio of skin cancer GEP tests at the 2022 ASDS Annual Meeting.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences is scheduled to present a company overview at Baird's 2022 Global Healthcare Conference on Tuesday, Sept. 13, 2022, at 2 p.m. ET

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Camilla Zuckero - Executive Director of IR & Corporate Communications Derek Maet

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 89.66% and 22.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present a company overview at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, Aug. 10, 2022, at 1:00 p.m. Eastern tim

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the second quarter and six months ended June 30, 2022, on Monday, Aug. 8, 2022.

Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -19.40% and 6.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2022 Results Conference Call May 9, 2022 4:30 PM ET Company Participants Camilla Zuckero - Executive Director of Investor Relations and Corporate Communicati

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -19.40% and 6.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -6.56% and 0.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences will release its financial results for the first quarter ended March 31, 2022, after the close of market on Monday, May 9, 2022.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present data on its skin cancer gene expression profile tests at the 18th European Association of Dermato Oncology (EADO) Congress.